MANGALAM DRUG & CHEM LTD
MANGALAM · General/Diversified · NSE
₹29
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for MANGALAM yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
3/9
Economic Moat
None
Confidence
16%
ROE
-43.1%
Debt/Equity
1.02
WACC
11.1%
Market Cap
₹46.12 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-6.8%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.04×
Short-term liquidity
Asset Turnover
0.79×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-14.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
MANGALAM · last 10 annual periods
ROE
-43.1%
ROCE
-6.8%
Operating Margin
—
Debt / Equity
1.02×
PE
122.1×
EV / EBITDA
10.9×
Historical Financials
MANGALAM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹447 Cr | ₹366 Cr | ₹365 Cr | ₹318 Cr | ₹232 Cr | -15.1% |
| EBITDA | ₹45.2 Cr | ₹22.1 Cr | ₹14.0 Cr | ₹36.3 Cr | ₹-14.1 Cr | — |
| EBIT | ₹38.9 Cr | ₹15.0 Cr | ₹2.8 Cr | — | — | -48.0% |
| PAT | ₹19.7 Cr | ₹1.3 Cr | ₹-9.1 Cr | ₹6.7 Cr | ₹-44.4 Cr | — |
| EPS (diluted) | ₹12.42 | ₹0.80 | ₹-5.73 | — | — | — |
| CFO | ₹25.7 Cr | ₹39.5 Cr | ₹3.9 Cr | ₹42.6 Cr | ₹4.2 Cr | -36.5% |
| CapEx | ₹-27.7 Cr | ₹-27.9 Cr | ₹-11.8 Cr | ₹-20.2 Cr | ₹-11.9 Cr | — |
| FCF | ₹-2.0 Cr | ₹11.6 Cr | ₹-7.9 Cr | ₹22.4 Cr | ₹-7.7 Cr | — |
| Total Assets | ₹328 Cr | ₹360 Cr | ₹334 Cr | ₹366 Cr | ₹315 Cr | -1.0% |
| Total Debt | ₹87.9 Cr | ₹88.5 Cr | ₹106 Cr | ₹96.2 Cr | ₹105 Cr | +4.7% |
| Shareholders' Equity | ₹151 Cr | ₹152 Cr | ₹136 Cr | ₹149 Cr | ₹103 Cr | -9.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MANGALAM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
LASA LASA | — | — | Pending | -17.6% | — |
BIOFILCHEM BIOFILCHEM | — | — | Pending | 3.0% | — |
VIVIMEDLAB VIVIMEDLAB | — | — | Pending | 90.9% | — |
VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
PAR PAR | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
—
Last payout
2017-12-21
₹0.50
Peak payout
₹0.50
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of MANGALAM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MANGALAM →
Compare
Head-to-head with peers
Compare MANGALAM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MANGALAMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.